Evaluating the Relationship Between Serum Level of Interleukin-6 and Rheumatoid Arthritis Severity and Disease Activity

Author(s): Elham Rajaei, Karim Mowla, Qodratollah Hayati*, Ali Ghorbani, Mehrdad Dargahi-Malamir, Saeed Hesam, Zeinab Deris Zayeri

Journal Name: Current Rheumatology Reviews

Volume 16 , Issue 3 , 2020

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Aim: The aim of this study was to evaluate the relationship between Interleukin-6 (IL-6) serum level and the severity and activity of Rheumatoid Arthritis (RA).

Methods: In this cross-sectional study, 120 RA patients referred to the rheumatology clinic, the patients were diagnosed by rheumatologists according to ACR / EULAR 2010 criteria. Based on DAS28 score the patients were divided into 4 groups: Remission, Mild, Moderate and Severe. Each group contained 30 patients. Serum levels of Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP), anti-Cyclic Citrullinated Peptide (anti-CCP) and Rheumatoid Factor (RF) and serum levels of IL-6, were measured. The relationship between these factors was measured and compared to the relationship between IL-6 and these factors, and the activity of the disease was evaluated based on DAS-28.

Results: This study showed that the serum level of IL-6 has a significant relationship with RA activity according to DAS-28 (P value <0.001). There is also a significant relationship between the ESR level, the number of painful joints, and the number of swollen joints, and the severity of the disease based on VAS.

Conclusion: Generally the findings of this study indicate that serum level of IL-6 plays an important role in the severity and activity of RA disease and can be considered as a determining factor in evaluating the severity of RA in RA patients and it is a good guide for a step up or down of treatment.

Keywords: Interleukin 6, rheumatoid arthritis, cytokine, DAS-28, cardiomyocytes, glycoprotein.

[1]
Mowla K, Saki MA, Jalali MT, Zayeri ZD. How to manage rheumatoid arthritis according to classic biomarkers and polymorphisms? Frontiers in Biology 2017; 12(3): 183-91.
[http://dx.doi.org/10.1007/s11515-017-1452-4]
[2]
Sinigaglia L, Varenna M, Girasole G, Bianchi G. Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin North Am 2006; 32(4): 631-58.
[http://dx.doi.org/10.1016/j.rdc.2006.07.002] [PMID: 17288969]
[3]
Forsblad D’Elia H, Larsen A, Waltbrand E, et al. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann Rheum Dis 2003; 62(7): 617-23.
[http://dx.doi.org/10.1136/ard.62.7.617] [PMID: 12810422]
[4]
Rajaei E, Haybar H, Mowla K, Zayeri Z. Metformin one in a million efficient medicines for rheumatoid arthritis complications: inflammation, Osteoblastogenesis, Cardiovascular disease, Malignancies. Curr Rheumatol Rev 2018.
[PMID: 30019648]
[5]
Haybar H, Shahrabi S, Deris Zayeri Z, Pezeshki S. Strategies to increase cardioprotection through cardioprotective chemokines in chemotherapy-induced cardiotoxicity. Int J Cardiol 2018; 269: 276-82.
[http://dx.doi.org/10.1016/j.ijcard.2018.07.087] [PMID: 30054148]
[6]
Liu XJ, Teichtahl A. P Wicks I. Interleukin-6 in rheumatoid arthritis-from the laboratory to the bedside. Curr Pharm Des 2015; 21(17): 2187-97.
[http://dx.doi.org/10.2174/1381612821666150310143332] [PMID: 25760299]
[7]
Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002; 4(3)(Suppl. 3): S233-42.
[http://dx.doi.org/10.1186/ar565] [PMID: 12110143]
[8]
De Benedetti F, Rucci N, Del Fattore A, et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 2006; 54(11): 3551-63.
[http://dx.doi.org/10.1002/art.22175] [PMID: 17075861]
[9]
Abdel Meguid MH, Hamad YH, Swilam RS, Barakat MS. Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage. Rheumatol Int 2013; 33(3): 697-703.
[http://dx.doi.org/10.1007/s00296-012-2375-7] [PMID: 22531887]
[10]
Chung S-J, Kwon Y-J, Park M-C, Park Y-B, Lee S-K. The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients. Yonsei Med J 2011; 52(1): 113-20.
[http://dx.doi.org/10.3349/ymj.2011.52.1.113] [PMID: 21155043]
[11]
Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res 2014; 2(4): 288-94.
[http://dx.doi.org/10.1158/2326-6066.CIR-14-0022] [PMID: 24764575]
[12]
Kang S, Tanaka T, Kishimoto T. Therapeutic uses of anti-interleukin-6 receptor antibody. Int Immunol 2015; 27(1): 21-9.
[http://dx.doi.org/10.1093/intimm/dxu081] [PMID: 25142313]
[13]
Aizu M, Mizushima I, Nakazaki S, et al. Changes in serum interleukin-6 levels as possible predictor of efficacy of tocilizumab treatment in rheumatoid arthritis. Mod Rheumatol 2018; 28(4): 592-8.
[http://dx.doi.org/10.1080/14397595.2017.1370766] [PMID: 28880691]
[14]
Rodríguez LM, Robles B, Marugán JM, Suárez A, Santos F. Urinary interleukin-6 is useful in distinguishing between upper and lower urinary tract infections. Pediatr Nephrol 2008; 23(3): 429-33.
[http://dx.doi.org/10.1007/s00467-007-0670-4] [PMID: 18040727]
[15]
Godaly G, Otto G, Burdick MD, Strieter RM, Svanborg C. Fimbrial lectins influence the chemokine repertoire in the urinary tract mucosa. Kidney Int 2007; 71(8): 778-86.
[http://dx.doi.org/10.1038/sj.ki.5002076] [PMID: 17228365]
[16]
van der Poll T, Keogh CV, Guirao X, Buurman WA, Kopf M, Lowry SF. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis 1997; 176(2): 439-44.
[http://dx.doi.org/10.1086/514062] [PMID: 9237710]
[17]
Shrivastava AK, Singh HV, Raizada A, et al. Inflammatory markers in patients with rheumatoid arthritis. Allergol Immunopathol (Madr) 2015; 43(1): 81-7.
[http://dx.doi.org/10.1016/j.aller.2013.11.003] [PMID: 24656623]
[18]
Baillet A, Gossec L, Paternotte S, et al. Evaluation of serum interleukin-6 level as a surrogate marker of synovial inflammation and as a factor of structural progression in early rheumatoid arthritis: results from a French national multicenter cohort. Arthritis Care Res (Hoboken) 2015; 67(7): 905-12.
[http://dx.doi.org/10.1002/acr.22513] [PMID: 25384758]
[19]
Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis 2010; 2(5): 247-56.
[http://dx.doi.org/10.1177/1759720X10378372] [PMID: 22870451]
[20]
Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. Bio- Med research international 2014; 2014
[http://dx.doi.org/10.1155/2014/698313]
[21]
Gaber W, Azkalany GS, Gheita TA, Mohey A, Sabry R. Clinical significance of serum interleukin-6 and− 174 G/C promoter polymorphism in Rheumatoid arthritis patients. Egypt Rheumatol 2013; 35(2): 107-13.
[http://dx.doi.org/10.1016/j.ejr.2012.11.002]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 3
Year: 2020
Published on: 22 September, 2020
Page: [249 - 255]
Pages: 7
DOI: 10.2174/1573397115666190206144223
Price: $65

Article Metrics

PDF: 24
HTML: 2
EPUB: 1
PRC: 1